|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Based on the result that SRSF6 RRM2 domain plays key roles in regulating AS and biological function, indacaterol, a β2-adrenergic receptor agonist approved for chronic obstructive pulmonary disease treatment, is identified as the inhibitor of SRSF6 to suppress CRC tumourigenicity.
|
29114070 |
2019 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Our results indicate CREB1 as a critical transcription factor of RRM2 which promotes tumor aggressiveness, and imply a significant correlation between CREB1 and RRM2 in CRC specimens.
|
27801665 |
2016 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Examination of clinical CRC specimens demonstrated that both RRM2 and E2F1 were elevated in most cancer tissues compared to the paired normal tissues.
|
26093293 |
2015 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
To investigate further the relevance of RRM2 and CRCs (colorectal cancers), we correlated the expression of RRM2 with the clinical outcome of CRCs.
|
23113760 |
2013 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
RRM2 represents a novel therapeutic target, thus highlighting the potential utility of RRM2 inhibitors in colorectal cancer with oncogenic KRAS.
|
21873171 |
2011 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.
|
21415168 |
2011 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
This strategy identified the signaling pathways that are affected by the prominent oncogenes HMGA1 and TACSTD2, established a yet unknown link between RRM2 and PLK1 and identified RPS2 and NOL5A as promising potential therapeutic targets in CRC.
|
20473941 |
2011 |
|
Colorectal Carcinoma
|
0.370 |
Biomarker
|
disease |
CTD_human |
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.
|
15814641 |
2005 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
In conclusion, FAM138B‑hsa‑miR‑30c‑CCNE2/RRM2 and the SSTR5‑AS1‑hsa‑miR‑15b‑5p‑CA2 ceRNA axes may be important mechanisms for HBV‑related HCC.
|
31638225 |
2019 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
We have previously demonstrated that suppression of RRM2 expression could substantially inhibit hepatocellular carcinoma cell proliferation and migration.
|
29710515 |
2018 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Furthermore, cell cycle and p53 signaling pathways may play vital mediatory roles; CDK1 may play crucial roles in HCC transformed from cirrhosis via cell cycle and p53 signaling pathways, and RRM2 might be involved in HCC transformed from cirrhosis via the p53 signaling pathway.
|
28640074 |
2017 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Thus, ADR-RRM2-TLPD represents a potential strategy for combined therapy of HCC overexpressing EGFR.
|
24060417 |
2013 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
RRM2 phosphoprotein interaction module construction in HCC can be a new route for studying the pathogenesis of HCC.
|
20798514 |
2010 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue.
|
18230555 |
2007 |
|
Adenocarcinoma of lung (disorder)
|
0.310 |
Biomarker
|
disease |
CTD_human |
c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.
|
27602772 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Ribonucleotide reductase subunit M1 and RRM2 mRNA expression in lung adenocarcinoma tumours is associated with clinical outcome to docetaxel/gemcitabine.
|
18414411 |
2008 |
|
Polycystic Ovary Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Sclerocystic Ovaries
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Colorectal Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.
|
15814641 |
2005 |
|
Malignant neoplasm of urinary bladder
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
Recently, high levels of RRM2 expression were reported to correlate with poor survival outcomes in patients with colorectal and bladder cancer.
|
25695839 |
2015 |
|
Bladder Neoplasm
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
Recently, high levels of RRM2 expression were reported to correlate with poor survival outcomes in patients with colorectal and bladder cancer.
|
25695839 |
2015 |
|
Malignant neoplasm of urinary bladder
|
0.220 |
Biomarker
|
disease |
RGD |
Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models.
|
21139803 |
2010 |
|
Malignant neoplasm of urinary bladder
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
We have shown frequent overexpression of RRM2 protein and its possible role in bladder cancer.
|
21166702 |
2010 |
|
Bladder Neoplasm
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
We have shown frequent overexpression of RRM2 protein and its possible role in bladder cancer.
|
21166702 |
2010 |